The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead's Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.
A Phase IIb/III study sponsored by NIAID is being stopped early after an interim analysis indicated that injected cabotegravir provided better protection than Gilead's Truvada.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
In an announcement over the weekend, the British drugmaker said the FDA had cited manufacturing issues in its complete response letter for cabotegravir and rilpivirine.